QTX125 |
Katalog-Nr.GC62411 |
QTX125 ist ein potenter und hochselektiver HDAC6-Inhibitor. QTX125 weist gegenÜber anderen HDACs eine hervorragende SelektivitÄt auf. QTX125 hat Antitumorwirkungen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1279698-31-5
Sample solution is provided at 25 µL, 10mM.
QTX125 is a potent and highly selective HDAC6 inhibitor. QTX125 exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects[1].
QTX125 (25-500 nM; 24-48 hours) treatment induces the subsequent apoptosis demonstrated by annexin V/propidium iodide double staining and the cleavage of caspase-9, caspase-8, caspase-3, and PARP[1]. In MCL cell lines MINO, REC-1, IRM-2 and HBL-2 cells, QTX125 (10 nM, 10 μM, 100 μM) induces dose-dependent hyperacetylation of α-tubulin[1].QTX125 has the strongest growth-inhibitory effect in Burkitt cell lymphoma, follicular lymphoma, and mantle cell lymphoma (MCL)[1].
QTX125 (60 mg/kg; i.p.; daily dosing for 5 days; for 4 weeks) treatment inhibits tumor growth in REC-1 or MINO cells xenografted in nude mice[1].
[1]. Montserrat PÉrez-Salvia, et al. In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. Haematologica. 2018 Nov;103(11):e537-e540.
Average Rating: 5
(Based on Reviews and 4 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *